Antibody-Drug Conjugate (ADC)

Antibody–drug conjugates (ADC) are one of the fastest growing technologies for therapeutics. The basic principle is a marriage between large molecules and small molecules. This approach comprises antibody conjugated to the small molecule drug, eg. cytotoxic payload via a chemical linker that is directed toward a target antigen expressed on the target cell surface, reducing systemic exposure and therefore toxicity. ADCs are complex molecules that require careful attention to various components. Selection of an appropriate target, an antibody, payload, and the configuration that the antibody is linked to the payload are key determinants of the safety and efficacy of ADCs.

Currently, ADC is most active in the oncology areas. There are already 13 ADC drug been approved by the FDA in 2024. There is significant scientific effort and investment in the ADC areas for new drug programs not only on the oncology but to other diseases areas such autoimmune or metabolic diseases.

Synovel Laboratory is highly experienced in ADC Linkers and payload design. We offer design and synthesis of specific linker and payloads based on requirement such as solubility, linker distance, the number of payloads, the identity of payload, de-conjugation method, cleavable or non-cleavable linkers and overall stability. We ensure that the new design will obtain Intellectual Property (IP) protection.

Synovel Laboratory also provides “One-stop-shop” service for antibody conjugation services via our network of laboratory. We will manage the whole process and deliver the final ADC drug candidates in a seamless manner.